
    
      Patients will receive the following conditioning regimen: fludarabine 40 mg/m2 IVBP daily for
      day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/
      day from day -5 through day -2, and ATG (Thymoglobulin®) at 0.5 mg/kg IV on day -3, and 2
      mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched
      donors). In addition to the above conditioning regimen all patients will receive TMI at a
      dose of 3Gy on days -3, -2 and -1. On day 0, the stem cell product will be infused according
      to BMT unit policy. Graft versus host disease (GVHD) prophylaxis will consist of
      administration of tacrolimus and methotrexate (see Section 8). Post-transplant evaluation
      will be done as per standard care with study data collected at day 30, 60, 90, 180, 365 and 2
      years.
    
  